AFC
GPCR icon

Ares Financial Consulting’s Structure Therapeutics GPCR Stock Holding History

Ares Financial Consulting’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.07K Buy
+20
New +$885 ﹤0.01% 997

Other funds holding GPCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Ares Financial Consulting's GPCR Position: Q2 2026 in Review

Ares Financial Consulting opened a new position in Structure Therapeutics (GPCR) in Q2 2026: 20 shares worth $1.07K. The stake represents ﹤0.01% of the portfolio and ranks #997 among its holdings.

191 funds tracked by Wall St. Rank hold GPCR as of Q2 2026.

  • Ares Financial Consulting held 20 shares of Structure Therapeutics worth $1.07K as of Q2 2026.
  • Structure Therapeutics was a new Ares Financial Consulting position in Q2 2026.
  • Structure Therapeutics made up ﹤0.01% of Ares Financial Consulting's portfolio in Q2 2026, its #997 holding.
  • 191 funds tracked by Wall St. Rank held Structure Therapeutics as of Q2 2026.

Based on Ares Financial Consulting's 13F filing for Q2 2026, filed 9 Jul 2026.